Company: MDCXW
Filing Date: 2025-11-17
Form Type: 424B3
Source: 0001062993-25-016880
Chunk: 14

Company: Medicus Pharma Ltd.
Filing Date: 2025-11-17
Form: 424B3
Chunk 14
---
7,150,268 |
| Total assets measured at fair value | $ |          7,150,268 |     | $ | -       |     | $ | -       |     | $ | 7,150,268 |
|                                     |   |  December 31, 2024 |     |   |         |     |   |         |     |   |           |
|                                     |   |            Level 1 |     |   | Level 2 |     |   | Level 3 |     |   |     Total |
| Current assets:                     |   |                    |     |   |         |     |   |         |     |   |           |
| Money market funds                  | $ |          4,164,323 |     | $ | -       |     | $ | -       |     | $ | 4,164,323 |
| Total assets measured at fair value | $ |          4,164,323 |     | $ | -       |     | $ | -       |     | $ | 4,164,323 |

The Company's cash equivalents are classified as Level 1. The fair value of the Company's cash and cash equivalents is determined based on market pricing that is both objective and publicly available. The Company did not reclassify any investments between levels in the fair value hierarchy during the periods presented.

9. Commitment and contingencies Commitments As part of the acquisition of Antev, the Company may be required to make future payments contingent on the achievement of specified milestones. These potential payments represent a commitment and may result in future cash outflows. As these milestones conditions are not considered probable, the Company has not recognized liability related to the contingent consideration. As of September 30, 2025, the Company had no other long-term commitments. Contingencies In the ordinary course of business, from time to time, the Company may be involved in various claims related to operations, rights, commercial, employment or other claims. Although such matters cannot be predicted with certainty, management does not consider the Company's exposure to such claims to be material to these condensed consolidated financial statements. 10. Segment reporting The Company manages the business activities on a consolidated basis and operates as one reportable segment that constitutes all of the consolidated entity, which is the business of advancing the clinical development program of the Company's product, while opportunistically identifying, evaluating, and acquiring accretive assets, properties or businesses. The Company's CODM is its Chief